Showing 1711-1720 of 4940 results for "".
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- Epicutis Launches Arctigenin Brightening Treatmenthttps://practicaldermatology.com/news/epicutis-launches-arctigenin-brightening-treatment/2468350/Epicutis announced that it has launched its Arctigenin Brightening Treatment, marking what the manufacturer called a significant shift in skin br
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- LEO Pharma Set for Five Late-Breaking Presentations at EADVhttps://practicaldermatology.com/news/leo-pharma-set-five-late-breaking-presentations-eadv/2468299/LEO Pharma A/S will present new clinical and real-world data from across its portfolio of products at the 33rd European Academy of Dermatology and Venereology (EADV) Congress from September 25-28 in Amsterdam, Netherlands, the company announced. Five coveted late-breaking presentations wi
- Lebrikizumab Shows Sustained AD Control Up to 3 Years in More 80%https://practicaldermatology.com/news/lebrikizumab-shows-sustained-ad-control-3-years-more-80/2468297/More than 80% of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to 3 years experienced sustained skin clearance with monthly maintenance dosing, Almirall
- NJ Legislator Pushes to Allow Sunscreen in Schoolshttps://practicaldermatology.com/news/nj-legislator-pushes-allow-sunscreen-schools/2468244/A new bill referred to New Jersey’s Assembly Education Committee would make the Garden State the 29th to pass legislation allowing direct access to sunscreen in schools, according to Insider NJ. Sunscreen is classified by the US Food and Drug Administration (FDA) as an over-the-counter dru
- Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in UShttps://practicaldermatology.com/news/tralokinumab-ldrm-300-mg2-ml-single-dose-autoinjector-available-us/2468195/The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisab
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked
- Long-Term Roflumilast Cream Shows Sustained Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/long-term-roflumilast-cream-shows-sustained-efficacy-pediatric-atopic-dermatitis/2468063/A recent open-label extension study showed more than 70% of pediatric patients aged 2-5 years treated with roflumilast cream 0.05% achieved EASI-75 after 56 weeks of treatment, with sustained efficacy and favorable safety in managing atopic dermatitis (AD). The